Cargando…

Network pharmacology identifies fisetin as a treatment for osteoporosis that activates the Wnt/β-catenin signaling pathway in BMSCs

BACKGROUND: Although fisetin may exist widely in many natural herbs, its anti-OP mechanism is still unclear. The aim of this study is to explore the molecular anti-osteoporosis (OP) mechanism of fisetin based on network pharmacology and cell experiments. METHODS: The target of fisetin was extracted...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Guihong, Zhao, Jinlong, Pan, Jianke, Yang, Yuan, Dou, Yaoxing, Yang, Weiyi, Zeng, Lingfeng, Liu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122799/
https://www.ncbi.nlm.nih.gov/pubmed/37087476
http://dx.doi.org/10.1186/s13018-023-03761-1
_version_ 1785029561749078016
author Liang, Guihong
Zhao, Jinlong
Pan, Jianke
Yang, Yuan
Dou, Yaoxing
Yang, Weiyi
Zeng, Lingfeng
Liu, Jun
author_facet Liang, Guihong
Zhao, Jinlong
Pan, Jianke
Yang, Yuan
Dou, Yaoxing
Yang, Weiyi
Zeng, Lingfeng
Liu, Jun
author_sort Liang, Guihong
collection PubMed
description BACKGROUND: Although fisetin may exist widely in many natural herbs, its anti-OP mechanism is still unclear. The aim of this study is to explore the molecular anti-osteoporosis (OP) mechanism of fisetin based on network pharmacology and cell experiments. METHODS: The target of fisetin was extracted by the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). The targets of OP were obtained by DisGeNET, GeneCards and the Comparative Toxicogenomics Database, and the targets of fisetin in OP were screened by cross-analysis. The protein–protein interaction (PPI) network was constructed by STRING, and the core targets were obtained. We performed gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses on common targets via the Database for Annotation, Visualization and Integrated Discovery. Finally, an in vitro cell experiment was used to verify the anti-OP effect and mechanism of fisetin. RESULTS: There are 44 targets of fisetin related to the treatment of OP. The PPI results suggest that CTNNB1, CCND1, TP53, JUN, and AKT1 are the core targets. A total of 259 biological process, 57 molecular function and 26 cell component terms were obtained from GO enrichment analysis. The results of KEGG pathway enrichment analysis suggested that fisetin treatment of OP may be related to the Wnt signaling pathway, estrogen signaling pathway, PI3K-Akt signaling pathway and other signaling pathways. In vitro cell experiments showed that fisetin significantly increased the expression levels of ALP, collagen I, osteopontin and RUNX2 in bone marrow mesenchymal stem cells (BMSCs) (p < 0.05). Fisetin also increased the gene expression levels of Wnt3 and β-catenin (CTNNB1) in BMSCs, which indicates that fisetin can regulate the Wnt/β-catenin signaling pathway and promote the osteogenic differentiation of BMSCs. CONCLUSIONS: Fisetin acts on multiple targets and pathways in the treatment of OP; mechanistically, it regulates the Wnt/β-catenin signaling pathway, which promotes the osteogenic differentiation of BMSCs and maintains bone homeostasis. The results of this study provide a theoretical basis for further study on the complex anti-OP mechanism of fisetin.
format Online
Article
Text
id pubmed-10122799
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101227992023-04-24 Network pharmacology identifies fisetin as a treatment for osteoporosis that activates the Wnt/β-catenin signaling pathway in BMSCs Liang, Guihong Zhao, Jinlong Pan, Jianke Yang, Yuan Dou, Yaoxing Yang, Weiyi Zeng, Lingfeng Liu, Jun J Orthop Surg Res Research Article BACKGROUND: Although fisetin may exist widely in many natural herbs, its anti-OP mechanism is still unclear. The aim of this study is to explore the molecular anti-osteoporosis (OP) mechanism of fisetin based on network pharmacology and cell experiments. METHODS: The target of fisetin was extracted by the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). The targets of OP were obtained by DisGeNET, GeneCards and the Comparative Toxicogenomics Database, and the targets of fisetin in OP were screened by cross-analysis. The protein–protein interaction (PPI) network was constructed by STRING, and the core targets were obtained. We performed gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses on common targets via the Database for Annotation, Visualization and Integrated Discovery. Finally, an in vitro cell experiment was used to verify the anti-OP effect and mechanism of fisetin. RESULTS: There are 44 targets of fisetin related to the treatment of OP. The PPI results suggest that CTNNB1, CCND1, TP53, JUN, and AKT1 are the core targets. A total of 259 biological process, 57 molecular function and 26 cell component terms were obtained from GO enrichment analysis. The results of KEGG pathway enrichment analysis suggested that fisetin treatment of OP may be related to the Wnt signaling pathway, estrogen signaling pathway, PI3K-Akt signaling pathway and other signaling pathways. In vitro cell experiments showed that fisetin significantly increased the expression levels of ALP, collagen I, osteopontin and RUNX2 in bone marrow mesenchymal stem cells (BMSCs) (p < 0.05). Fisetin also increased the gene expression levels of Wnt3 and β-catenin (CTNNB1) in BMSCs, which indicates that fisetin can regulate the Wnt/β-catenin signaling pathway and promote the osteogenic differentiation of BMSCs. CONCLUSIONS: Fisetin acts on multiple targets and pathways in the treatment of OP; mechanistically, it regulates the Wnt/β-catenin signaling pathway, which promotes the osteogenic differentiation of BMSCs and maintains bone homeostasis. The results of this study provide a theoretical basis for further study on the complex anti-OP mechanism of fisetin. BioMed Central 2023-04-22 /pmc/articles/PMC10122799/ /pubmed/37087476 http://dx.doi.org/10.1186/s13018-023-03761-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Liang, Guihong
Zhao, Jinlong
Pan, Jianke
Yang, Yuan
Dou, Yaoxing
Yang, Weiyi
Zeng, Lingfeng
Liu, Jun
Network pharmacology identifies fisetin as a treatment for osteoporosis that activates the Wnt/β-catenin signaling pathway in BMSCs
title Network pharmacology identifies fisetin as a treatment for osteoporosis that activates the Wnt/β-catenin signaling pathway in BMSCs
title_full Network pharmacology identifies fisetin as a treatment for osteoporosis that activates the Wnt/β-catenin signaling pathway in BMSCs
title_fullStr Network pharmacology identifies fisetin as a treatment for osteoporosis that activates the Wnt/β-catenin signaling pathway in BMSCs
title_full_unstemmed Network pharmacology identifies fisetin as a treatment for osteoporosis that activates the Wnt/β-catenin signaling pathway in BMSCs
title_short Network pharmacology identifies fisetin as a treatment for osteoporosis that activates the Wnt/β-catenin signaling pathway in BMSCs
title_sort network pharmacology identifies fisetin as a treatment for osteoporosis that activates the wnt/β-catenin signaling pathway in bmscs
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122799/
https://www.ncbi.nlm.nih.gov/pubmed/37087476
http://dx.doi.org/10.1186/s13018-023-03761-1
work_keys_str_mv AT liangguihong networkpharmacologyidentifiesfisetinasatreatmentforosteoporosisthatactivatesthewntbcateninsignalingpathwayinbmscs
AT zhaojinlong networkpharmacologyidentifiesfisetinasatreatmentforosteoporosisthatactivatesthewntbcateninsignalingpathwayinbmscs
AT panjianke networkpharmacologyidentifiesfisetinasatreatmentforosteoporosisthatactivatesthewntbcateninsignalingpathwayinbmscs
AT yangyuan networkpharmacologyidentifiesfisetinasatreatmentforosteoporosisthatactivatesthewntbcateninsignalingpathwayinbmscs
AT douyaoxing networkpharmacologyidentifiesfisetinasatreatmentforosteoporosisthatactivatesthewntbcateninsignalingpathwayinbmscs
AT yangweiyi networkpharmacologyidentifiesfisetinasatreatmentforosteoporosisthatactivatesthewntbcateninsignalingpathwayinbmscs
AT zenglingfeng networkpharmacologyidentifiesfisetinasatreatmentforosteoporosisthatactivatesthewntbcateninsignalingpathwayinbmscs
AT liujun networkpharmacologyidentifiesfisetinasatreatmentforosteoporosisthatactivatesthewntbcateninsignalingpathwayinbmscs